补肺息喘汤对慢性阻塞性肺疾病稳定期疗效及炎症因子、CXCL13和TLR4水平影响  

Therapeutic Effect of Bufei Xichuan Decoction(补肺息喘汤)on Stable COPD Patients and Its Impact on Levels of Inflammatory Factors,CXCL13 and TLR4 in Patients

作　　者：陈周明[1] 李炳荣[1] 骆松梅[1] 张胜娟[1] CHEN Zhouming;LI Bingrong;LUO Songmei;ZHANG Shengjuan(Lishui Central Hospital,Lishui 323000,Zhejiang,China)

机构地区：[1]丽水市中心医院,浙江丽水323000

出　　处：《中华中医药学刊》2025年第3期182-185,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号)。

摘　　要：目的 探讨补肺息喘汤对慢性阻塞性肺疾病稳定期(SCOPD)患者疗效及对炎症因子、TLR4和CXCL13水平影响。方法 选择医院于2022年4月—2024年4月SCOPD患者160例,将其随机分为观察组80例与对照组80例。对照组吸入茚达特罗格隆溴铵,观察组在对照组基础上服用补肺息喘汤。两组治疗周期8周。比较两组治疗疗效;治疗前后肺功能,6MWT和CAT问卷评分,炎症因子、TLR4和CXCL13水平变化。结果 观察组总有效率高于对照组(P<0.05)。两组治疗8周SCOPD患者FEV1/FVC、PEF、FEV1和6MWT高于治疗前,而CAT评分、TNF-α、IL-6、IL-8、TLR4和CXCL13水平低于治疗前(P<0.05);观察组治疗8周SCOPD患者FEV1/FVC、PEF、FEV1和6MWT高于对照组,而CAT评分、TNF-α、IL-6、IL-8、TLR4和CXCL13水平低于对照组(P<0.05)。结论 补肺息喘汤对SCOPD患者治疗疗效显著,可减轻细胞炎症反应,及降低TLR4和CXCL13水平,值得临床借鉴。Objective To explore the therapeutic effect of Bufei Xichuan Decoction(补肺息喘汤)on stable stage chronic ob-structive pulmonary disease(SCOPD)patients and its impact on the levels of inflammatory factors,Toll like receptor 4(TLR4)and chemokine CXC ligand 13(CXCL13)in patients.Method A total of 160 SCOPD patients from April 2022 to April 2024 in the hospital were divided into observation group and control group,each with 80 cases.The patients of the control group inhaled indatelopram bromide,while those of the observation group took Bufei Xichuan Decoction on the basis of the control group.The treatment period for both groups was 8 weeks.The therapeutic effects of two groups was compared.The changes in lung function,6-minute walking distance(6MWT),COPD assessment test(CAT)questionnaire scores,inflammatory factors,TLR4 and CX-CL13 before and after treatment were compared.Result The effective rate of the observation group was higher than that of the control group(P<0.05).After 8 weeks of treatment,the values of FEV1/FVC,PEF,FEV1 and 6MWT of the two groups were higher than those before treatment,while the CAT score,the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8),TLR4 and CXCL13 were lower than those before treatment(P<0.05).The values of FEV1/FVC,PEF,FEV1 and 6MWT of the observation group were higher than those of the control group,while the CAT score,the levels of TNF-α,IL-6,IL-8,TLR4 and CXCL13 were lower than those of the control group after treatment(P<0.05).Conclusion-Bufei Xichuan Decoction has a significant therapeutic effect on SCOPD patients,reducing cellular inflammatory response and low-ering the levels of TLR4 and CXCL13,which is worthy of clinical reference.

关 键 词：补肺息喘汤 慢性阻塞性肺疾病稳定期 疗效 炎症因子 TOLL样受体4 趋化因子CXC配体13 

分 类 号：R256.1[医药卫生—中医内科学]